Module

Burkitt's and Associated Lymphomas

Source: Lymphoma Annual Update 2005

Burkitt's and Associated Lymphomas


Program Director: Julie M. Vose, MD

Faculty:

  • Ariela Noy, MD

CME CREDIT INFORMATION

Release Date: 08/31/05

Expiration Date: 08/30/06


Physicians: maximum of 1 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.2 Nursing CE credits

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review the difference of the biology of Burkitt's and Burkitt's-like lymphomas from other B-cell neoplasms

  • Discuss efficacy and safety of existing and new treatment options for Burkitt's lymphoma

  • Describe prognostic features of Burkitt's lymphoma


Content includes:

  • Characteristics of Burkitt's Lymphoma
  • CODOX-M/IVAC for Burkitt's Lymphoma
  • HyperCVAD for Burkitt's Lymphoma
  • Rituximab in Burkitt's Lymphoma
  • Short, Intensive Chemotherapy for Burkitt's Lymphoma
  • Plasmablastic Lymphoma
  • Biology of BL Tumors
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grants provided by:

Educational grants support only the CME-certified components of this program.